$3.89
Arbutus Biopharma is a biotechnology business based in the US. Arbutus Biopharma shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma employs 73 staff and has a trailing 12-month revenue of around $13 million.
Our top picks for where to buy Arbutus Biopharma stock
How to buy Arbutus Biopharma stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ABUS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Arbutus Biopharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Arbutus Biopharma stock price (NASDAQ: ABUS)
Use our graph to track the performance of ABUS stocks over time.Arbutus Biopharma shares at a glance
Latest market close | $3.92 |
---|---|
52-week range | $1.69 - $3.89 |
50-day moving average | $3.23 |
200-day moving average | $2.58 |
Wall St. target price | $4.40 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.44 |
Is it a good time to buy Arbutus Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arbutus Biopharma price performance over time
Historical closes compared with the close of $3.92 from 2024-07-25
1 week (2024-07-19) | 6.23% |
---|---|
1 month (2024-06-26) | 30.23% |
3 months (2024-04-26) | 43.59% |
6 months (2024-01-26) | 64.71% |
1 year (2023-07-26) | 82.33% |
---|---|
2 years (2022-07-26) | 65.40% |
3 years (2021-07-26) | 44.65% |
5 years (2019-07-26) | 117.78% |
Arbutus Biopharma financials
Revenue TTM | $13 million |
---|---|
Gross profit TTM | $-45,389,000 |
Return on assets TTM | -29.31% |
Return on equity TTM | -57.54% |
Profit margin | 0% |
Book value | $0.64 |
Market Capitalization | $703.9 million |
TTM: trailing 12 months
Arbutus Biopharma share dividends
We're not expecting Arbutus Biopharma to pay a dividend over the next 12 months.
Have Arbutus Biopharma's shares ever split?
Arbutus Biopharma's shares were split on a 1:5 basis on 3 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma shares which in turn could have impacted Arbutus Biopharma's share price.
Arbutus Biopharma share price volatility
Over the last 12 months, Arbutus Biopharma's shares have ranged in value from as little as $1.69 up to $3.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma's is 1.957. This would suggest that Arbutus Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Arbutus Biopharma overview
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc. ; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc. ; Acuitas Therapeutics, Inc. ; and Antios Therapeutics, Inc.
Frequently asked questions
nullWhat percentage of Arbutus Biopharma is owned by insiders or institutions?
Currently 22.287% of Arbutus Biopharma shares are held by insiders and 44.287% by institutions. How many people work for Arbutus Biopharma?
Latest data suggests 73 work at Arbutus Biopharma. When does the fiscal year end for Arbutus Biopharma?
Arbutus Biopharma's fiscal year ends in December. Where is Arbutus Biopharma based?
Arbutus Biopharma's address is: 701 Veterans Circle, Warminster, PA, United States, 18974 What is Arbutus Biopharma's ISIN number?
Arbutus Biopharma's international securities identification number is: CA03879J1003 What is Arbutus Biopharma's CUSIP number?
Arbutus Biopharma's Committee on Uniform Securities Identification Procedures number is: 87911B209
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question